List of Excipients in Branded Drug NEOMYCIN POLYMYXIN B SULFATES AND DEXAMETHASONE

Generic Drugs Containing NEOMYCIN POLYMYXIN B SULFATES AND DEXAMETHASONE

Company	Ingredient	NDC	Excipient
MWI/VetOne	neomycin sulfate, polymyxin b sulfate and dexamethasone	13985-028	BENZALKONIUM CHLORIDE
MWI/VetOne	neomycin sulfate, polymyxin b sulfate and dexamethasone	13985-028	HYDROCHLORIC ACID
MWI/VetOne	neomycin sulfate, polymyxin b sulfate and dexamethasone	13985-028	HYPROMELLOSES
MWI/VetOne	neomycin sulfate, polymyxin b sulfate and dexamethasone	13985-028	POLYSORBATE 20
MWI/VetOne	neomycin sulfate, polymyxin b sulfate and dexamethasone	13985-028	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in NEOMYCIN POLYMYXIN B SULFATES AND DEXAMETHASONE?

# Of NDCs	Excipient
12	BENZALKONIUM CHLORIDE
12	HYDROCHLORIC ACID
1	HYDROXYPROPYL METHYLCELLULOSE
5	HYPROMELLOSE
6	HYPROMELLOSES

Excipient Strategy and Commercial Opportunities for Neomycin Polymyxin B Sulfates and Dexamethasone

Last updated: August 30, 2026

Neomycin polymyxin B sulfates and dexamethasone is an established ophthalmic antibacterial-corticosteroid combination marketed in suspension and ointment dosage forms. Its core active-ingredient composition is mature, and commercial differentiation depends primarily on excipient performance, preservative strategy, delivery format, manufacturing consistency, and channel economics rather than on new active-ingredient claims.

The strongest opportunities are preservative-free ophthalmic products, improved suspension systems, unit-dose packaging, low-blur ointments, and differentiated products for post-procedure or short-duration ocular use. A conventional generic suspension or ointment faces limited composition-of-matter risk but remains exposed to FDA product-quality requirements, bioequivalence challenges, container-closure issues, and physician preference.

What products contain neomycin polymyxin B sulfates and dexamethasone?

The combination is used as a prescription ophthalmic anti-infective and corticosteroid. The reference products commonly associated with the combination are Maxitrol ophthalmic suspension and Maxitrol ophthalmic ointment.

Product characteristic	Ophthalmic suspension	Ophthalmic ointment
Neomycin sulfate	Equivalent to 3.5 mg neomycin base/mL or equivalent labeled strength	Equivalent labeled strength
Polymyxin B sulfate	10,000 units/mL or equivalent labeled strength	Equivalent labeled strength
Dexamethasone	1 mg/mL or equivalent labeled strength	Equivalent labeled strength
Dosage form	Sterile aqueous suspension	Sterile ophthalmic ointment
Primary excipient challenge	Particle suspension, redispersibility, viscosity, preservative tolerance	Uniform drug distribution, spreadability, melting and congealing behavior
Main patient concern	Stinging, shaking requirement, preservative exposure	Blurred vision and ocular residue
Main commercial opportunity	Preservative-free and easy-to-redisperse suspension	Lower-blur, lower-residue ointment

The FDA labeling describes the combination for steroid-responsive inflammatory ocular conditions where bacterial infection or the risk of bacterial infection exists. Corticosteroid use requires clinical control because steroids can delay healing, raise intraocular pressure, and worsen certain viral, fungal, or untreated infectious conditions. [1]

What excipients are used in the ophthalmic suspension?

The suspension formulation uses excipients that control wetting, viscosity, tonicity, pH, preservation, and physical stability. Public labeling for the reference suspension identifies excipient classes including hydroxypropyl methylcellulose, polysorbate 20, sodium chloride, sodium citrate, benzalkonium chloride, and pH-adjusting agents. [1]

Excipient or excipient class	Functional role	Development issue
Hydroxypropyl methylcellulose	Suspending and viscosity-enhancing agent	Excess viscosity can impair drop formation and patient administration
Polysorbate 20	Wetting and dispersion aid	Can affect interfacial stability and may contribute to oxidation or impurity formation
Sodium chloride	Tonicity adjustment	Must be balanced against active salts and buffer capacity
Sodium citrate	Buffering and pH control	pH can affect dexamethasone stability, comfort, and polymyxin behavior
Benzalkonium chloride	Preservative	Repeated exposure may cause ocular-surface irritation or toxicity
Hydrochloric acid or sodium hydroxide	pH adjustment	Process control must prevent local pH excursions
Purified water	Vehicle	Sterility, endotoxin, and particulate controls are mandatory

The suspension must remain physically uniform during storage and must redisperse after settling. A product that requires aggressive shaking, forms a hard cake, produces variable drop concentrations, or clogs the dropper has a weak commercial profile even if it meets basic potency specifications.

How should the suspension excipient system be optimized?

The development target should be a low-to-moderate-viscosity suspension with rapid redispersion, controlled sedimentation, low ocular irritation, and consistent delivered volume. The main formulation variables are:

1. Particle-size distribution of each active ingredient.
2. Wetting efficiency of the surfactant.
3. Suspending-polymer concentration.
4. Density mismatch between particles and vehicle.
5. Flocculation behavior.
6. pH and ionic strength.
7. Dropper geometry and dispensing force.

A flocculated suspension can settle relatively quickly but redisperse easily. A deflocculated system may remain visually uniform longer but can form a compact sediment that is difficult to redisperse. The preferred profile depends on the reference product, product specifications, and FDA bioequivalence strategy.

The excipient composition should be designed together with the manufacturing process. Milling, micronization, high-shear mixing, order of addition, deaeration, sterile filtration of the vehicle, and aseptic filling can affect final performance. A formulation patent based only on a routine polymer or buffer substitution would likely have limited durability unless it produces a measurable and unexpected improvement.

What excipients are used in the ophthalmic ointment?

The ophthalmic ointment generally uses a mineral-oil and white-petrolatum base. The anhydrous vehicle supports chemical stability and avoids the preservative requirements associated with an aqueous multidose product. [2]

The principal development variables are:

• Drug-particle wetting and uniform distribution.
• Ointment yield stress and extrusion force.
• Spreadability across the ocular surface.
• Melting and softening profile at ocular temperature.
• Residence time.
• Visual blur.
• Tube compatibility and extractables.
• Microbial quality during filling and use.

Ointment provides longer residence than an aqueous drop but can cause substantial temporary visual blurring. A commercial opportunity exists for a lower-residue or lower-blur ointment that preserves drug uniformity and ocular retention. That opportunity is technically difficult because reducing the oil or petrolatum fraction can reduce residence time and alter dose uniformity.

What preservative-free opportunities exist?

Preservative-free delivery is the clearest excipient-led opportunity. Benzalkonium chloride is effective and widely used, but repeated exposure can irritate the ocular surface. A preservative-free product could target patients with ocular-surface disease, frequent dosing, contact-lens-related sensitivity, or post-procedure treatment needs.

Preservative-free suspension

A single-dose vial is the most straightforward preservative-free format. It avoids the multidose microbial-preservation problem but increases:

• Packaging cost.
• Fill-finish complexity.
• Plastic consumption.
• Patient handling burden.
• Distribution and inventory costs.

A preservative-free multidose container would have greater commercial appeal but would require a validated sterile barrier or proprietary dispensing system. The container-closure and microbial-in-use package could provide stronger defensible intellectual property than a routine excipient substitution.

Alternative preservatives

Replacing benzalkonium chloride with another preservative may reduce some tolerability concerns but does not automatically create a superior product. The alternative must demonstrate preservative effectiveness, compatibility with the active ingredients, acceptable ocular tolerability, and stability across the labeled shelf life. The FDA evaluates ophthalmic products under quality, sterility, container-closure, and product-performance requirements rather than by excipient identity alone. [3]

What formulations are protected by patents?

The active combination is old, and the original product composition is unlikely to provide a meaningful current barrier to ordinary generic entry. The commercial value of new intellectual property would therefore come from a specific formulation, container, manufacturing process, or use.

Potential patent subjects include:

Patent subject	Commercial value	Main validity or enforcement risk
Preservative-free multidose container	High if microbial performance is demonstrated	Prior-art and obviousness challenges
Specific particle-size distribution	Moderate to high if linked to bioavailability or redispersion	Routine optimization argument
Controlled-flocculation suspension	Moderate	Reproducibility and claim-construction issues
Low-blur ointment	Moderate	Difficult proof of unexpected performance
Novel in situ gel or mucoadhesive vehicle	High if clinically useful	Regulatory and formulation complexity
Improved dropper or dose-metering system	Moderate	Device prior art
Manufacturing process controlling polymyxin or neomycin impurities	Moderate	Trade-secret protection may be stronger
Postoperative method of use	Variable	Narrow labeling and patent-enforcement limits

A robust patent estate would use several claim categories: composition claims, performance-defined claims, container-closure claims, process claims, and method-of-use claims. Claims should be tied to measurable properties such as redispersion time, particle-size limits, delivered-dose uniformity, preservative exposure, or reduced ocular irritation.

Method-of-use patents are more vulnerable to noninfringing-label strategies. A generic manufacturer may seek approval with a label that omits a patented indication or dosing regimen, subject to applicable FDA rules and litigation outcomes.

When does this combination lose exclusivity?

The combination has already passed the period of original regulatory and patent exclusivity associated with legacy products. A standard generic strategy would generally proceed through the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act, provided the applicant can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for the dosage form. [3]

Exclusivity category	Current commercial significance
New chemical entity exclusivity	Expired for this legacy combination
Five-year new-drug exclusivity	Not applicable to a mature combination
Three-year clinical-investigation exclusivity	Not expected to block a conventional equivalent
Pediatric exclusivity	No known current blocking role
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Active composition-of-matter patent	No meaningful legacy barrier expected
Formulation or device patent	Potentially relevant for a newly differentiated product

The relevant regulatory question is not whether the active ingredients are old. It is whether the proposed product matches the reference product in dosage form, route, strength, active ingredients, and performance characteristics.

What is the Orange Book status of neomycin polymyxin B sulfates and dexamethasone?

The FDA Orange Book is the controlling source for listed patents, exclusivity, therapeutic-equivalence evaluations, and approved reference products. [4] For a mature ophthalmic combination, Orange Book analysis should focus on:

• The exact reference listed drug.
• Suspension versus ointment dosage form.
• Active patent listings.
• Approved generic equivalents.
• Any therapeutic-equivalence rating.
• Paragraph IV certifications.
• Whether a formulation or device patent is listed against the specific reference product.

A generic suspension should not be treated as interchangeable with an ointment merely because the active ingredients and strengths are similar. Dosage form, excipient system, delivery characteristics, labeling, and reference-product designation remain important.

Which companies are challenging the reference product?

Generic competition is likely to come from established ophthalmic manufacturers, contract development and manufacturing organizations, and specialty generic companies with sterile fill-finish capacity. The most credible competitors will have:

• Aseptic ophthalmic manufacturing.
• Experience with suspension products.
• Validated low-bioburden and sterility controls.
• Dropper or tube container-closure capabilities.
• Access to ophthalmic regulatory and clinical development expertise.
• Commercial relationships with wholesalers, hospitals, and ophthalmology practices.

A company with only conventional oral-solid-dose capabilities faces a substantial manufacturing barrier. Sterile ophthalmic manufacturing is more capital-intensive and operationally sensitive than production of ordinary tablets or capsules.

What Paragraph IV challenges and litigation risks exist?

A conventional ANDA applicant could certify under Paragraph IV if an Orange Book-listed patent is asserted against the reference product. For a legacy combination with no material active patent barrier, the principal risks are more likely to involve:

• Product-quality deficiencies.
• Failure to demonstrate equivalent performance.
• Inadequate stability.
• Inconsistent suspension redispersion.
• Container-closure defects.
• Patent claims directed to a new preservative-free or device-enabled formulation.
• Trade-secret disputes involving manufacturing know-how.

A Paragraph IV dispute would typically be more relevant to a newly patented reformulation than to the underlying neomycin-polymyxin B-dexamethasone active combination. No prominent current settlement structure is associated with the legacy active combination in the public regulatory record cited here. Any product-specific litigation assessment should be tied to the relevant Orange Book entry and court docket.

Is there biosimilar risk for this product?

There is no biosimilar risk. Neomycin, polymyxin B, and dexamethasone are not biologics, and the combination is regulated as a conventional drug product. Competition will arise through generic, reformulated, or device-enabled products rather than through the biosimilar pathway.

The closest competitive products are other ophthalmic antibacterial-corticosteroid combinations, including products containing tobramycin and dexamethasone or neomycin, polymyxin B, and hydrocortisone. These products compete for similar prescribing situations but are not automatically substitutable. Differences in active ingredients, spectrum, steroid potency, dosage form, labeling, and therapeutic-equivalence rating affect market access.

How does the patent estate compare with competing ophthalmic combinations?

Product category	Active-ingredient differentiation	Patent strength for legacy product	Main commercial defense
Neomycin-polymyxin B-dexamethasone	Mature triple combination	Low for core composition	Brand recognition, supply reliability, differentiated formulation
Tobramycin-dexamethasone	Alternative aminoglycoside plus steroid	Low to moderate depending on reformulation	Prescriber familiarity and formulation quality
Neomycin-polymyxin B-hydrocortisone	Different corticosteroid	Low	Lower-cost generic availability
Fluoroquinolone-steroid products	Different antibacterial class	Variable	Broader prescribing familiarity and newer product positioning
Preservative-free combinations	Delivery and tolerability differentiation	Potentially moderate to high	Container, formulation, and clinical-performance claims

A new product will have a better commercial position if it solves a visible administration or tolerability problem. A simple generic suspension with the same conventional excipients will compete mainly on price and supply.

What manufacturing and IP barriers affect commercialization?

The principal manufacturing barriers are sterility assurance, active-ingredient uniformity, particle control, filling accuracy, and stability. Polymyxin B and neomycin are sulfate salts, so the formulation has a relatively high ionic load. That can affect pH, osmolality, viscosity, and compatibility with polymers and surfactants.

Key development controls include:

• Particle-size measurement for suspended actives.
• Assay and content uniformity throughout the container.
• Redispersion after accelerated and long-term storage.
• Delivered-dose uniformity.
• Visible and subvisible particulate testing.
• Sterility and preservative-effectiveness testing.
• Extractables and leachables assessment.
• Container-closure integrity.
• Compatibility with ophthalmic tips, tubes, and caps.

Manufacturing know-how can create a meaningful barrier even where patent protection is weak. Control of particle wetting, order of addition, shear exposure, and filling temperature may determine whether a product consistently meets performance specifications.

What generic launch scenarios exist?

Low-cost conventional generic

This product uses a conventional preserved suspension or petrolatum-based ointment. It has the lowest development cost but faces heavy price competition and limited brand differentiation.

Premium preservative-free product

This product targets ocular-surface-sensitive patients and post-procedure use. It can command a higher net price if packaging, tolerability, and distribution costs remain manageable.

Unit-dose institutional product

Hospitals and ambulatory surgery centers may value single-use packaging and reduced preservative exposure. The tradeoff is higher packaging and logistics expense.

Improved suspension product

A rapidly redispersible, low-viscosity product could compete on ease of use and dose consistency. The opportunity is strongest if the improvement is supported by human-factors data or clinically relevant tolerability evidence.

Ointment-plus-drop commercial portfolio

A manufacturer could offer both suspension and ointment presentations under one brand or authorized-generic strategy. This can increase formulary coverage and capture different prescribing preferences.

What is the revenue exposure and commercial opportunity?

Revenue exposure is concentrated in ophthalmic prescription channels, retail pharmacy, hospital purchasing, and ophthalmology practices. The legacy product is vulnerable to generic substitution because the actives are old and the treatment duration is generally short. Short courses can reduce absolute patient spend while increasing the importance of pharmacy availability and formulary placement.

The highest-value commercial attributes are:

1. Preservative-free delivery.
2. Reliable sterile supply.
3. Easy redispersion.
4. Reduced visual blur for ointment.
5. Unit-dose convenience.
6. Competitive wholesale acquisition cost.
7. Therapeutic-equivalence status where available.
8. Stable shelf life with low batch failure risk.

Licensing opportunities are more likely to involve proprietary ophthalmic containers, preservative-free systems, sterile fill-finish capacity, or regional commercialization rights than rights to the underlying active combination. A specialty pharmaceutical company could license a formulation platform and use it for several ophthalmic combinations, improving the economics of development.

Key Takeaways

• Neomycin polymyxin B sulfates and dexamethasone is a mature ophthalmic antibacterial-corticosteroid combination.
• Core active-ingredient patents and original regulatory exclusivities do not present a material barrier to ordinary generic entry.
• Suspension development depends on redispersion, particle-size control, viscosity, dose uniformity, and sterile manufacturing.
• Ointment development depends on drug distribution, spreadability, residence time, visual blur, and tube compatibility.
• Preservative-free products are the strongest excipient-led commercial opportunity.
• A proprietary multidose preservative-free container could provide stronger patent value than a routine excipient substitution.
• No biosimilar pathway applies; competition will come from generics and reformulations.
• Paragraph IV risk is more relevant to newly patented formulations or devices than to the legacy active combination.
• Manufacturing know-how may provide greater practical protection than weak composition patents.
• Commercial success will depend on differentiation, supply reliability, therapeutic equivalence, and sterile ophthalmic execution.

FAQs

Can neomycin polymyxin B dexamethasone be developed as a preservative-free eye drop?

Yes. A single-dose preservative-free suspension is the most straightforward approach. A preservative-free multidose product is commercially more attractive but requires a validated microbial-control container system.

Is benzalkonium chloride necessary in this ophthalmic combination?

No. It is a common preservative in multidose ophthalmic products, but a product may use single-dose packaging or another validated preservation strategy. The alternative must satisfy sterility, stability, compatibility, and preservative-effectiveness requirements.

Can a new excipient combination receive patent protection?

Potentially. Patentability depends on the specific composition and whether it produces a non-obvious, measurable benefit such as improved redispersion, reduced irritation, improved stability, or lower visual blur.

Is an ointment automatically therapeutically equivalent to the ophthalmic suspension?

No. Suspension and ointment are different dosage forms. Regulatory substitutability depends on the FDA-approved reference product, dosage form, strength, labeling, and therapeutic-equivalence determination.

What is the most defensible commercial formulation strategy?

A preservative-free, easy-to-administer suspension supported by a differentiated container-closure system offers the strongest combination of patient value, commercial positioning, and potential intellectual-property protection.

References

1. U.S. Food and Drug Administration. (n.d.). Maxitrol: Neomycin sulfate, polymyxin B sulfate, and dexamethasone ophthalmic suspension prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Maxitrol: Neomycin sulfate, polymyxin B sulfate, and dexamethasone ophthalmic ointment prescribing information. DailyMed.

3. U.S. Food and Drug Administration. (2023). Draft guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. FDA.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Ophthalmic preparations and sterility requirements. USP.